To study in two national cohorts of HSCT survivors, treated in different time periods, the prevalence and risk factors of metabolic syndrome, endothelial dysfunction (as a sign of vascular damage) and the clinical phenotypes of accelerated aging so…
ID
Source
Brief title
Condition
- Other condition
- Vascular hypertensive disorders
Synonym
Health condition
metabool syndroom, veroudering
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Prevalence and risk factors of metabolic syndrome (and it's components) and
endothelial dysfunction
Secondary outcome
Prevalence and risk factors of accelerated aging
Background summary
In previous studies the prevalence of both metabolic and vascular chronic
health problems has been shown to be high in survivors of hematopoietic stem
cell transplantation (HSCT). Co-existence of these and other aging-related
conditions (*multimorbidity*) at young adult age, suggests accelerated aging
occurs in HSCT survivors, potentially leading to impaired quality of life,
disability and early mortality. Previous studies on these chronic health
conditions in HSCT survivors only included small patient numbers and did not
examine the interrelation between these health problems nor potentially
modifiable lifestyle risk factors.
Study objective
To study in two national cohorts of HSCT survivors, treated in different time
periods, the prevalence and risk factors of metabolic syndrome, endothelial
dysfunction (as a sign of vascular damage) and the clinical phenotypes of
accelerated aging so that high risk survivor groups can be identified and
preventive strategies can be developed to improve health related quality of
life and prevent early mortality in HSCT survivors.
Study design
Observational prospective study
Study burden and risks
Burden is limited to time investment, but tests are non-invasive except for a
blood sample, preferably fasting, (that is also needed voor care) and no risk
for participants is anticipated
Heidelberglaan 25
Utrecht 3584 CS
NL
Heidelberglaan 25
Utrecht 3584 CS
NL
Listed location countries
Age
Inclusion criteria
Survivors of hematopoietic stem cell transplantation in childhood (at age <=18
yr) for a hematological malignancy between 01-01-2002 and 01-01-2021, who are 4
years of age or older at inclusion and in follow-up in the late effects clinic
of the Princess Maxima Center
Exclusion criteria
Treatment for second malignancy
No understanding of the Dutch language or illiterate
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL83998.041.23 |